SG11201912043QA - Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions - Google Patents

Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions

Info

Publication number
SG11201912043QA
SG11201912043QA SG11201912043QA SG11201912043QA SG11201912043QA SG 11201912043Q A SG11201912043Q A SG 11201912043QA SG 11201912043Q A SG11201912043Q A SG 11201912043QA SG 11201912043Q A SG11201912043Q A SG 11201912043QA SG 11201912043Q A SG11201912043Q A SG 11201912043QA
Authority
SG
Singapore
Prior art keywords
prodrug
treatment
medical conditions
cancerous medical
cancerous
Prior art date
Application number
SG11201912043QA
Inventor
Reza Fathi
Mark Levitt
Terry Plasse
Danielle Abramson
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of SG11201912043QA publication Critical patent/SG11201912043QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976Trypsin; Chymotrypsin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11201912043QA 2017-07-21 2018-07-13 Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions SG11201912043QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762535376P 2017-07-21 2017-07-21
US201762574449P 2017-10-19 2017-10-19
US201762589734P 2017-11-22 2017-11-22
PCT/IB2018/000881 WO2019016595A1 (en) 2017-07-21 2018-07-13 Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions

Publications (1)

Publication Number Publication Date
SG11201912043QA true SG11201912043QA (en) 2020-02-27

Family

ID=65014605

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912043QA SG11201912043QA (en) 2017-07-21 2018-07-13 Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions

Country Status (14)

Country Link
US (1) US20190022088A1 (en)
EP (1) EP3654979A4 (en)
JP (1) JP2020527582A (en)
KR (1) KR20200031567A (en)
CN (1) CN110785172A (en)
AU (1) AU2018303799A1 (en)
CA (1) CA3070037A1 (en)
CL (1) CL2020000096A1 (en)
IL (1) IL271878A (en)
PH (1) PH12019502817A1 (en)
RU (1) RU2020107706A (en)
SG (1) SG11201912043QA (en)
WO (1) WO2019016595A1 (en)
ZA (1) ZA201908545B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494392A (en) * 2020-04-14 2020-08-07 广州领晟医疗科技有限公司 Composition for treating acute lung injury and application thereof
CN111494602B (en) * 2020-04-14 2023-06-02 广州领晟医疗科技有限公司 Composition for treating acute pancreatitis and application thereof
CN113559100B (en) * 2021-08-30 2023-01-17 广州领晟医疗科技有限公司 Composition for treating lung injury and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534498A (en) * 1992-01-30 1996-07-09 Corvas International, Inc. Trypsin inhibitors
US7342018B2 (en) * 1998-07-20 2008-03-11 Wilex Ag Urokinase inhibitors and uses thereof
WO2003070229A2 (en) * 2002-02-22 2003-08-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of proteinase inhibitors in the treatment of autoimmune diseases
DE10323898A1 (en) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
EP3309556B1 (en) * 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome

Also Published As

Publication number Publication date
RU2020107706A3 (en) 2021-10-15
WO2019016595A1 (en) 2019-01-24
IL271878A (en) 2020-02-27
CL2020000096A1 (en) 2020-08-28
CN110785172A (en) 2020-02-11
EP3654979A1 (en) 2020-05-27
US20190022088A1 (en) 2019-01-24
PH12019502817A1 (en) 2020-09-14
KR20200031567A (en) 2020-03-24
EP3654979A4 (en) 2021-04-14
JP2020527582A (en) 2020-09-10
ZA201908545B (en) 2021-02-24
RU2020107706A (en) 2021-08-23
AU2018303799A1 (en) 2019-12-19
CA3070037A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL272948B1 (en) Enpp1 inhibitors and their use for the treatment of cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
EP3325473A4 (en) Compounds and uses thereof in the treatment of cancers and other medical conditions
IL268469B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
PL3416957T3 (en) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes
PT3416945T (en) 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
IL271878A (en) Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions
HK1257239A1 (en) Medicine for preventing and treating obesity and use of the medicine
IL272097A (en) Compounds for the prevention and treatment of medical disorders and uses thereof
EP3723742C0 (en) Use of fluoroethylnormemantine for the prevention and treatment of anxiety
EP3697387A4 (en) Combination of as1411 and sapc-dops for the treatment of glioblastoma multiforme
IL269121A (en) Usl-311 for use in the treatment of cancer
HK1257591A1 (en) Medicine for preventing and treating pathologic kidney tissue damage and use of the medicine
IL261984B (en) Sultiame for the treatment of sleep apnea
LT3353164T (en) Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
PT3580211T (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer